These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12624312)

  • 1. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.
    Katzan IL; Hammer MD; Furlan AJ; Hixson ED; Nadzam DM;
    Stroke; 2003 Mar; 34(3):799-800. PubMed ID: 12624312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
    Katzan IL; Furlan AJ; Lloyd LE; Frank JI; Harper DL; Hinchey JA; Hammel JP; Qu A; Sila CA
    JAMA; 2000 Mar; 283(9):1151-8. PubMed ID: 10703777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
    Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV
    Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
    Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
    Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.
    Adelman EE; Scott PA; Skolarus LE; Fox AK; Frederiksen SM; Meurer WJ
    J Stroke Cerebrovasc Dis; 2016 Jan; 25(1):67-73. PubMed ID: 26419527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.
    Uchino K; Massaro L; Jovin TG; Hammer MD; Wechsler LR
    J Stroke Cerebrovasc Dis; 2010; 19(6):417-23. PubMed ID: 21051004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
    Xian Y; Xu H; Lytle B; Blevins J; Peterson ED; Hernandez AF; Smith EE; Saver JL; Messé SR; Paulsen M; Suter RE; Reeves MJ; Jauch EC; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
    Eissa A; Krass I; Bajorek BV
    J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
    Saposnik G; Demchuk A; Tu JV; Johnston SC;
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):876-82. PubMed ID: 23102741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.
    Scott PA; Frederiksen SM; Kalbfleisch JD; Xu Z; Meurer WJ; Caveney AF; Sandretto A; Holden AB; Haan MN; Hoeffner EG; Ansari SA; Lambert DP; Jaggi M; Barsan WG; Silbergleit R
    Acad Emerg Med; 2010 Oct; 17(10):1062-71. PubMed ID: 21040107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.
    Graham GD
    Stroke; 2003 Dec; 34(12):2847-50. PubMed ID: 14605319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-hospital delays to stroke thrombolysis: paradoxical effect of early arrival.
    Romano JG; Muller N; Merino JG; Forteza AM; Koch S; Rabinstein AA
    Neurol Res; 2007 Oct; 29(7):664-6. PubMed ID: 18173904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
    Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED
    JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Study of Adverse Events After Intravenous Tissue-Type Plasminogen Activator Treatment of Acute Ischemic Stroke.
    Fernandez-Gotico H; Lightfoot T; Meighan M
    J Neurosci Nurs; 2017 Feb; 49(1):31-36. PubMed ID: 28060219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.